Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc.verified

ADVM

Price:

$7.865

Market Cap:

$163.25M

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorpor...[Read more]

Industry

Biotechnology

IPO Date

2014-07-31

Stock Exchange

NASDAQ

Ticker

ADVM

The ROE as of July 2024 (TTM) for Adverum Biotechnologies, Inc. (ADVM) is -90.38%

According to Adverum Biotechnologies, Inc.’s latest financial reports and current stock price. The company's current ROE is -90.38%. This represents a change of 268.73% compared to the average of -24.51% of the last 4 quarters.

Adverum Biotechnologies, Inc. (ADVM) Historical ROE (quarterly & annually)

How has ADVM ROE performed in the past?

The mean historical ROE of Adverum Biotechnologies, Inc. over the last ten years is -49.06%. The current -90.38% ROE has changed 84.23% with respect to the historical average. Over the past ten years (40 quarters), ADVM's ROE was at its highest in in the March 2015 quarter at -3.40%. The ROE was at its lowest in in the September 2023 quarter at -32.02%.

Quarterly (TTM)
Annual

Average

-49.06%

Median

-36.48%

Minimum

-140.37%

Maximum

-16.99%

Adverum Biotechnologies, Inc. (ADVM) ROE by Quarter and Year

Discovering the peaks and valleys of Adverum Biotechnologies, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 180.83%

Maximum Annual ROE = -16.99%

Minimum Annual Increase = -100.70%

Minimum Annual ROE = -140.37%

Quarterly (TTM)
Annual
YearROEChange
2023-140.37%64.88%
2022-85.14%84.96%
2021-46.03%70.14%
2020-27.05%-26.60%
2019-36.86%2.09%
2018-36.10%18.33%
2017-30.51%-42.17%
2016-52.76%180.83%
2015-18.79%10.54%
2014-16.99%-100.70%

Adverum Biotechnologies, Inc. (ADVM) Average ROE

How has ADVM ROE performed in the past?

The current ROE of Adverum Biotechnologies, Inc. (ADVM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-90.51%

5-year avg

-67.09%

10-year avg

-49.06%

Adverum Biotechnologies, Inc. (ADVM) ROE vs. Peers

How is ADVM’s ROE compared to its peers?

Adverum Biotechnologies, Inc.’s ROE is greater than uniQure N.V. (-121.60%), greater than Rocket Pharmaceuticals, Inc. (-53.10%), greater than Rhythm Pharmaceuticals, Inc. (-179.26%), greater than Solid Biosciences Inc. (-55.94%), greater than MeiraGTx Holdings plc (-62.36%), greater than Aerovate Therapeutics, Inc. (-70.24%), greater than Adagene Inc. (-37.48%), greater than Acrivon Therapeutics, Inc. Common Stock (-49.66%), greater than Rezolute, Inc. (-60.90%), greater than AN2 Therapeutics, Inc. (-57.16%), greater than Passage Bio, Inc. (-68.53%), greater than Absci Corporation (-52.74%), greater than Kezar Life Sciences, Inc. (-50.35%), less than Oncternal Therapeutics, Inc. (46.29%), less than Kodiak Sciences Inc. (398.51%), greater than Galmed Pharmaceuticals Ltd. (-48.22%), greater than Affimed N.V. (-136.05%), greater than Mereo BioPharma Group plc (-73.04%), greater than Homology Medicines, Inc. (-100.91%), greater than Stoke Therapeutics, Inc. (-65.47%), greater than Atreca, Inc. (-195.22%), greater than TCR2 Therapeutics Inc. (-89.51%),

Build a custom stock screener for Adverum Biotechnologies, Inc. (ADVM) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Adverum Biotechnologies, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Adverum Biotechnologies, Inc. (ADVM) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Adverum Biotechnologies, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the ROE?

How can you use the ROE?

What is Adverum Biotechnologies, Inc.'s ROE?

How is the ROE calculated for Adverum Biotechnologies, Inc. (ADVM)?

What is the highest ROE for Adverum Biotechnologies, Inc. (ADVM)?

What is the 3-year average ROE for Adverum Biotechnologies, Inc. (ADVM)?

What is the 5-year average ROE for Adverum Biotechnologies, Inc. (ADVM)?

How does the current ROE for Adverum Biotechnologies, Inc. (ADVM) compare to its historical average?